Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1989-9-26
|
pubmed:abstractText |
Silymarin, the active principle of the milk thistle Silybum marianum, protects experimental animals against various hepatotoxic substances. To determine the effect of silymarin on the outcome of patients with cirrhosis, a double blind, prospective, randomized study was performed in 170 patients with cirrhosis. 87 patients (alcoholic 46, non-alcoholic 41; 61 male, 26 female; Child A, 47; B, 37; C, 3; mean age 57) received 140 mg silymarin three times daily. 83 patients (alcoholic 45, non-alcoholic 38; 62 male, 21 female; Child A, 42; B, 32; C, 9: mean age 58) received a placebo. Non-compliant patients and patients who failed to come to a control were considered as 'drop outs' and were withdrawn from the study. All patients received the same treatment until the last patient entered had finished 2-years of treatment. The mean observation period was 41 months. There were 10 drop outs in the placebo group and 14 in the treatment group. In the placebo group, 37 (+2 drop outs) patients had died, and in 31 of these, death was related to liver disease. In the treatment group, 24 (+4 drop outs) had died, and in 18 of these, death was related to liver disease. The 4-year survival rate was 58 +/- 9% (S.E.) in silymarin-treated patients and 39 +/- 9% in the placebo group (P = 0.036). Analysis of subgroups indicated that treatment was effective in patients with alcoholic cirrhosis (P = 0.01) and in patients initially rated 'Child A' (P = 0.03). No side effects of drug treatment were observed.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0168-8278
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
105-13
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2671116-Adult,
pubmed-meshheading:2671116-Cause of Death,
pubmed-meshheading:2671116-Clinical Trials as Topic,
pubmed-meshheading:2671116-Double-Blind Method,
pubmed-meshheading:2671116-Female,
pubmed-meshheading:2671116-Flavonoids,
pubmed-meshheading:2671116-Humans,
pubmed-meshheading:2671116-Liver Cirrhosis,
pubmed-meshheading:2671116-Liver Cirrhosis, Alcoholic,
pubmed-meshheading:2671116-Liver Function Tests,
pubmed-meshheading:2671116-Male,
pubmed-meshheading:2671116-Middle Aged,
pubmed-meshheading:2671116-Prospective Studies,
pubmed-meshheading:2671116-Random Allocation,
pubmed-meshheading:2671116-Silymarin
|
pubmed:year |
1989
|
pubmed:articleTitle |
Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.
|
pubmed:affiliation |
1st Department of Gastroenterology and Hepatology, University of Vienna, Austria.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|